Glomerular disorder

This phase 2 trial is testing whether a single infusion of a patient's own genetically modified immune cells, called C-CAR168, can safely and effectively treat lupus nephritis that has not responded to standard therapies. The cells are designed to target and eliminate specific im…

This early-phase trial tests whether a single infusion of CD19 CAR-T cells, called TranspoCART19, is safe and can push severe lupus nephritis into remission. Lupus nephritis is a serious kidney complication of lupus that often resists standard treatments. Ten adults with refracto…

This trial is testing an experimental therapy called FKC289 for people with a type of kidney disease called primary membranous nephropathy that has come back or not responded to standard treatment. FKC289 uses the patient's own immune cells, which are modified in the lab to recog…

This early-stage trial is testing an experimental drug called SNC116 in people with refractory systemic lupus erythematosus (SLE), a form of lupus that hasn't improved with standard treatments. The study aims to see if a single intravenous infusion of SNC116 is safe and tolerable…

This study looks back at the experiences of 35 adults with a rare kidney disease called C3G who received the drug iptacopan through a special early access program in Spain. Researchers will collect information on patient health, lab results, and how the disease responds to treatm…

This phase 2 trial is investigating whether an experimental drug called ARGX-121 can improve outcomes for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either ARGX-121 or a placebo, while continuing their usual care. The …

Researchers are testing whether adding atrasentan to standard supportive care improves kidney structure and function in adults with IgA nephropathy, a condition where the immune system damages the kidneys. About 20 participants will take atrasentan 0.75 mg once daily for 52 weeks…

This early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…

This trial tests the long-term safety and effectiveness of povetacicept, an investigational drug given as a subcutaneous injection, in adults with immunoglobulin A nephropathy (IgAN), a kidney disease that can lead to kidney failure. Participants who completed the earlier parent …

This phase 3 trial is testing whether adding the drug obinutuzumab to the standard treatment (mycophenolate mofetil and corticosteroids) can improve outcomes for people with active lupus nephritis, a serious kidney complication of lupus. The study will enroll 70 adults aged 18-65…

This trial asks whether mycophenolate mofetil (MMF) can help people with IgA nephropathy whose disease hasn't improved with standard care. About 104 adults with biopsy-confirmed refractory IgA nephropathy will be randomly assigned to take either MMF or the steroid prednisolone fo…

This study evaluates a new care model for people with lupus nephritis, a kidney complication of lupus. The approach uses telemedicine visits and clinical pharmacist practitioners to provide medication support, adherence help, and remote monitoring, with oversight from specialists…

This phase 3 trial is testing whether sibeprenlimab, an investigational drug given as an injection every 4 weeks, can help children and adolescents with IgA nephropathy. The study includes about 24 participants aged 2 to 17 with biopsy-confirmed disease. The main goal is to see i…

This early-stage trial is testing whether a single infusion of universal STAR-T cells—a type of engineered immune cell that targets both CD19 and BCMA—can safely and effectively treat two autoimmune kidney diseases: IgA nephropathy and primary membranous nephropathy. The study wi…

This study is testing whether an experimental drug called FXS6837 can safely reduce protein in the urine and help preserve kidney function in people with IgA nephropathy, a disease that can lead to kidney failure. About 60 patients who previously completed a shorter study of FXS6…

This phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3,…

This phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…

This phase II trial tests whether obinutuzumab, a B-cell targeting antibody, can alone achieve complete kidney response in people with pure class V lupus nephritis—a form of lupus kidney disease with no approved treatments. Participants receive up to four infusions over seven mon…

This early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The…

This study compares two treatments—albumin and fresh frozen plasma—for children with idiopathic nephrotic syndrome who have fluid buildup that doesn't respond to standard diuretics. The goal is to see which approach resolves swelling faster and more safely. Fifty-six children age…

This study tests whether combining rituximab with a low dose of mycophenolate mofetil can safely and effectively treat lupus nephritis in children. Lupus nephritis is a serious kidney complication of lupus. The trial enrolls children aged 3 to 18 with active kidney inflammation. …

This early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…

This phase 2 trial tests whether dapagliflozin, a drug used for diabetes and heart failure, can reduce harmful antibodies and prevent relapses in people with membranous nephropathy, an autoimmune kidney disease. The study enrolls 20 adults who have had a recent rise in anti-PLA2R…

This trial tests a one-time treatment called CAR-T cell therapy for people with systemic lupus erythematosus (lupus) that hasn't improved with standard medications. The therapy uses a patient's own immune cells, which are modified in a lab to find and destroy the B cells that dri…

This Phase 3 trial tests whether BHV-1400 can safely reduce protein in the urine and preserve kidney function in 420 adults with IgA nephropathy. Participants are randomly assigned to receive either the drug or a placebo by injection. The main goal is to see if BHV-1400 lowers pr…

This early-stage trial tests a one-time infusion of donor immune cells (CAR-γδT cells) designed to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 adults whose di…

This early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…

This early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…

This Phase 2 trial tests SLN12140, an experimental drug, in 48 adults with IgA nephropathy whose disease is not well-controlled by standard treatments. Participants receive different doses of SLN12140 or a placebo for 36 weeks, then all can receive the drug for another year. The …

This study will follow 50 adults with IgA nephropathy who are taking sparsentan. Researchers want to see how the drug affects protein in the urine (albuminuria), a key sign of kidney damage. The study is observational, meaning it just watches what happens in real-world use, witho…

This early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…

This early-stage trial tests a drug called NM8074 in 10 adults with IgA Nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage, after 99 days of treatment. Participants must have a…

This early-phase trial tests a new drug called NM8074 in 18 adults with C3 Glomerulopathy (C3G), a rare kidney disease. The drug is given by IV over several weeks to see if it is safe and can reduce protein in the urine, a sign of kidney damage. Researchers will also check how th…

This study tests an experimental drug called FXS6837 in 60 adults with IgA nephropathy, a kidney disease. Participants will receive either the drug or a placebo for about 6 months. The main goal is to see if the drug lowers protein in the urine, a sign of kidney damage.

This study tests whether regularly measuring the amount of mycophenolate mofetil in the blood helps more people with lupus kidney disease achieve kidney remission. One hundred adults with active lupus nephritis will be split into two groups: one gets standard dosing, the other ge…

This Phase 2 trial tests an experimental drug called HS-10542 in 90 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either a high dose, low dose, or placebo for a set period. The main goal is to see if the drug reduces prot…

This study looks at whether giving the drug rituximab early, when signs of the disease reappear in the blood, can prevent relapses in people with certain types of vasculitis (GPA and MPA). About 70 adults who have been on maintenance rituximab for at least 18 months will be rando…

This early study tests a new treatment called ES-NK cells for people with severe lupus nephritis that hasn't responded to standard care. The therapy uses specially grown immune cells to try to control the disease. About 5 to 9 participants will receive different doses to check sa…

This early-stage trial will test a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus or scleroderma that have not responded to standard treatments. The children will receive a single infusion of these cells, and researchers will…

This early-phase trial tests a new type of immune cell therapy called UCAR-T for people with a tough-to-treat kidney condition called refractory idiopathic membranous nephropathy. The therapy uses specially engineered cells to target and attack certain immune cells that may be dr…

This early-stage trial tests a new drug called YK012 in 66 adults with a severe form of kidney disease called primary membranous nephropathy that has not responded to standard treatments. YK012 is a bispecific antibody designed to reduce the immune system's attack on the kidneys.…

This study tests a new drug, SIM0278, in 60 adults with active lupus nephritis, a kidney disease caused by lupus. Participants will receive either SIM0278 or a placebo, and researchers will check if the drug helps improve kidney function over 52 weeks. The goal is to see if SIM02…

This Phase 3 trial tests whether adding avacopan to standard treatment helps people with severe ANCA vasculitis and serious kidney damage. About 130 participants will receive either avacopan or a placebo alongside usual care. The goal is to see if more patients recover kidney fun…

This study tests a drug called obinutuzumab in 10 adults with a kidney condition called nephrotic syndrome that keeps coming back despite standard treatments. The goal is to see if a single course can keep patients relapse-free for at least 12 months by deeply depleting certain i…

This study tests an investigational drug called LP-005 in 46 adults with complement-mediated kidney disease, a condition where the immune system attacks the kidneys. Participants receive the injection alongside their standard care. The goal is to see if the drug can reduce protei…

This early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…

This early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the dise…

This study tests whether Shenqi Yishen Granules, a traditional Chinese medicine, can reduce protein in the urine of adults with IgA nephropathy, a kidney disease. Researchers will compare the granules to a placebo in 102 participants over several months. The goal is to see if the…

This early-phase trial will test BCT301, a type of immune cell made from stem cells, in 10 people with severe autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these cells after a short course of chemotherapy. The main goal is to check safe…

This Phase 2 study tests an injectable drug called CM313 in 106 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if CM313 is safe and can help control the disease by reducing kidney damage. Participants will receive either CM313 or…

This study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …

This study compares a 12-week steroid course to the standard 24-week course for adults with steroid-sensitive nephrotic syndrome, a kidney condition that causes protein leakage and swelling. Researchers want to see if the shorter treatment can keep the disease from coming back ju…

This observational study tests whether levels of MPO-DNA complexes in the blood can serve as a reliable biomarker for disease activity in systemic lupus erythematosus (SLE). Researchers will compare MPO-DNA levels in 90 participants with active versus inactive lupus, and check ho…

This study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of l…

This study investigates whether levels of a protein called RNASE1 in the blood can serve as a biomarker for lupus nephritis, a serious kidney complication of systemic lupus erythematosus (SLE). Researchers will compare RNASE1 levels in 128 adults with SLE, some with lupus nephrit…

Lupus nephritis is a serious kidney complication of lupus that can lead to kidney failure. This study investigates whether levels of neutrophil extracellular traps (NETs)—web-like structures released by immune cells—in the blood can predict how well patients respond to therapy. R…

This study looks at whether measuring anti-alpha-actinin antibodies in the blood can help identify active lupus nephritis (kidney inflammation) in people with lupus. Researchers will compare antibody levels with findings from standard kidney biopsies in 96 adults. If the blood te…

Membranous nephropathy is a rare autoimmune kidney disease where antibodies attack the kidney and can cause nephrotic syndrome. Rituximab is a routine treatment that depletes B cells, but researchers suspect it also boosts regulatory T cells, which help control immune reactions. …

This study is testing whether a prediction model can accurately forecast how quickly kidney function declines in people with primary membranous nephropathy, a kidney disease that can lead to nephrotic syndrome and kidney failure. Researchers will follow 128 adults with biopsy-con…

This study looks at whether two simple blood test ratios—neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein to serum albumin ratio (CAR)—can predict which hospitalized adults with lupus nephritis will need intensive care or die during their stay. Researchers will compare…

This study follows 300 adults in China who have had a kidney transplant due to glomerulonephritis (GN), a type of kidney disease. The goal is to see how often GN comes back after the transplant and what factors might influence that. Participants will be monitored for three years …

This study looks at whether two blood-based inflammation markers, called SII and SIRI, can help track disease activity and predict kidney flares in people with lupus nephritis, a type of kidney inflammation caused by lupus. Researchers will follow 100 adults with confirmed lupus …

This study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…

This study investigates whether the triglyceride-glucose (TyG) index, a simple blood-based measure of insulin resistance, can predict early signs of atherosclerosis in people with lupus nephritis. Researchers will measure carotid artery thickness and plaque in 156 adults with lup…

This trial tests an AI-powered teaching platform called iLN, which uses a large language model to help medical students learn about lupus nephritis. Fifty fourth-year medical students are randomly assigned to either use iLN or attend a traditional PowerPoint lecture. The study me…

This study follows 120 adults with ANCA-associated vasculitis, an autoimmune disease, who are receiving rituximab therapy. Researchers will collect blood samples over time to look for immune cell changes that signal a coming relapse. The goal is to find biomarkers that help docto…

This study looks at what changes occur in the kidneys, urine, and blood when people with IgA nephropathy (IgAN) experience loin pain. Researchers will use MRI scans and lab tests to compare findings during a pain episode and when pain-free. The goal is to better understand the ca…

This study tests whether an electronic health record alert can help primary care doctors refer patients with blood and protein in their urine to a kidney specialist. About 1,200 adults with these high-risk signs will be included. The goal is to see if the alert improves referral …

This study will observe 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient profiles, treatment patterns, and clinical outcomes over 24 months. The goal is to understand how these drugs …

This early-stage study tests a single injection of RG002C0106 in 24 adults to see how kidney function affects the drug's levels and safety. Participants have either normal kidneys or mild-to-moderate kidney impairment. The goal is to gather basic information, not to treat the dis…

This study aims to find genetic and protein markers that can predict whether patients with membranous nephropathy, a kidney disease, will respond to the drug rituximab. Researchers will analyze stored blood and tissue samples from 120 patients and healthy volunteers. The goal is …

This study looks back at medical records of about 83 adults with C3 glomerulopathy (C3G), a rare kidney disease, who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year of treatment. The goal is…

This study will check if people with lupus nephritis have low zinc levels and how that relates to kidney function. Researchers will measure zinc, urea, creatinine, and other markers in 75 participants. The goal is to better understand the connection, not to test a treatment.

This study will measure levels of a protein called IL-33 in the blood of 150 people: lupus patients with kidney inflammation, lupus patients without kidney issues, and healthy volunteers. Researchers want to see if higher IL-33 levels are linked to more severe disease, especially…